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Intestinal epithelial cells have evolved to coexist with the rich microflora of the gut lumen. Multiple  
mechanisms  ensure  proper  reaction  to  microorganisms  –  epithelium  is  usually  unresponsive  to 
commensal but can react to pathogenic bacteria. Epithelial cells are the “sensors” of the inside world of
the  gut  lumen.  Release  of  interferons  is  one  of  the  regulatory  mechanisms  directing  the  immune 
response to pathogens and the inflammatory reaction to epithelial injury. Overreaction to bacteria due 
to epithelium damage e.g. during the inflammatory bowel disease (IBD), may lead to overstimulation 
of the immune system and progressing destruction of the intestinal epithelial layer. Earlier studies in 
Drosophila fruitfly have shown that damage of the intestinal mucosa mobilizes the Jak/Stat signalling 
pathway which stimulates intestinal epithelial stem cells to regenerate the gut epithelium. Interferon 
receptors utilize Jak/Stat signalling and mutations in this pathway are linked to IBD in humans. We 
were interested to investigate the role of interferons in intestinal epithelium regeneration in mouse. We 
found that mouse colonic epithelial cells CMT-93 produce type I and type III interferon mRNA in 
response to poly(I:C) - a dsRNA analogue - and to  Listeria infection. Interferon beta was found to 
inhibit CMT-93 proliferation. When comparing type I interferon receptor-deficient (IFNAR1-/-) and 
wildtype primary mouse intestinal epithelial  cells, we found slight differences in their  proliferation 
rates in vitro. Epithelial cells from the small intestine had increased Type I and III interferon mRNA in 
response to  intraoral  Listeria  but  not  to  Salmonella  infections.  We have also discovered  that  lung 
epithelial cells upregulate type I and III interferons in response to coinfection with Influenza virus and 
Legionella pneumophila but not to Legionella infection alone. Finally we have developed a method for 
short term culture of primary intestinal epithelial cells that we intend to use for future experiments. 
Although the differences in proliferation between IFNAR1-/- and wildtype primary intestinal epithelial 




Darmepithelzellen leben im ständigen Kontakt mit der Darmmikroflora. Ihre Reaktion auf pathogene 
Mikroorganismen  unterscheidet  sich  von  der  auf  kommensale  Bakterien.  Diese  Epithelzellen 
funktionieren wie Sensoren des Darmlumens. Freisetzung von Interferonen ist dabei einer der Wege auf 
das antimikrobielle Immunsystem Einfluss zu nehmen. Zu starke Reaktionen auf Bakterien, die durch 
Schädigung  des  Epithels  während  chronisch-entzündlicher  Erkrankung  (IBD)  verursacht  werden, 
führen  zur  Überreaktion  des  Immunsystems  und  zu  fortschreitender  Schädigung  des  Epithels. 
Experimente  an  Drosophila-Fliegen  zeigten,  dass  im  beschädigten  Darm  der  Jak/Stat 
Signaltransduktionsweg die Stammzellen des Darmepithels stimuliert damit diese die Epithelschicht 
schnell  regenerieren  können.  Interferon  Rezeptoren  mobilisieren  Jak-Stat  Signaltransduktion. 
Mutationen der im Interferon-Signaltransduktionsweg eingesetzten Jak/Stat Moleküle, wurden mit IBD 
in Zusammenhang gebracht. Hier untersuchten wir die Rolle der Interferone bei der Darmregeneration 
in einem Mausmodell. Wir haben festgestellt, dass CMT-93 Maus-Kolonepithelzellen  als Antwort auf 
poly(I:C) - ein dsRNA Analogon - und Listerien-Infektion Typ I und Typ III Interferone produzieren. 
Interferon-beta Stimulation senkte die Proliferationsrate von CMT-93 Zellen. Zwischen Mäusen ohne 
Typ I Interferon Rezeptor (IFNAR1-/-) und C57BL/6 Wildtyp-Mäusen haben wir kleine Unterschiede 
in  Proliferationsraten  von  Primärdarmepithelzellen  ermittelt.  Dünndarm-Epithelzellen  exprimierten 
auch mehr Typ I und III Interferon-mRNA nach Infektion mit Listerien, nicht aber mit Salmonellen. 
Wir haben auch entdeckt, dass Typ I und III Interferone nach Koinfektion mit Influenza Virus und 
Legionellen  in  Lungenepithelzellen  produziert  wurden,  nicht  aber  nach  Infektion  mit  Legionella 
alleine.  Für  weiterführende  Studien  wurde  eine  Methode  zur  kurzfristigen  Kultur  von  primären 
Darmepithelzellen entwickelt. Obwohl die Unterschiede in der Proliferation zwischen Epithelzellen aus 
IFNAR1-/- und Wildtyp-Mäusen gering waren, es ist möglicht dass Interferone zu  IBD-Entwicklung 
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Introduction
First to see and first to react – the innate immune system
The innate immune system is the host's primary defense mechanism against a plethora of invading 
organisms. It can recognize pathogens and use cell mediated or humoral immunity to eliminate them. 
Furthermore it alerts the cells of the adaptive immune system, T and B lymphocytes, that carry specific 
antigen  receptors  and  perform  various  functions.  Lymphocytes  can  kill  infected  cells  directly  or 
indirectly by providing help to the innate immune system - activating phagocytic cells and natural killer 
(NK) cells.  Lymphocytes  also produce  antibodies  that  increase the visibility  of  the pathogens and 
neutralize them.
To combat specific infections and to keep the immune system in shape cells need a way to convey their 
messages to a specific audience, i.e. target cells. Cell-cell contacts are often used for local signalling 
e.g. during lymphocyte maturation and on-site activities of adaptive immune response, but to mediate 
long-range signals, cells secrete signalling molecules called cytokines that can stimulate proliferation 
of  specific  cells,  shift  the  flavour  of  immune  responses  or  bring  the  response  to  a  halt  once  the  
pathogen has been eradicated. Infected cells produce cytokines that signal the immune system about 
infection and can also induce a protective state in the neighbouring cells. One class of such molecules 
are  interferons  (IFNs),  named for their  ability  to  interfere with virus  replication in  cells  that  have 
already been exposed to inactivated virus (Isaacs & Lindenmann 1957). They induce an antiviral state 
in the infected and neighbouring cells (Fig. 1) by inducing protein kinase R (PKR), 2'5'-oligoadenylate 
synthetase  (2'5'-OAS),  RNases,  Mx  proteins  and  other  proteins  that  lead  to  inhibition  of  virus 
transcription, translation and virus particle assembly, lead to viral RNA degradation etc.. Interferons 
act also on non-infected cells - they activate players of the innate immune system e.g. NK cells and 
macrophages,  to  destroy  infected  and  tumor  cells.  Interferons  affect  adaptive  immune  cells  either 
directly, by  stimulating  Th1  cell  development  that  promotes  destruction  of  infected  cells  by 
macrophages, or indirectly, by increasing presentation of viral antigens via upregulation of class I and 
class II MHC molecules on the infected cells.
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Fig. 1. A virus-infected cell produces Type I Interferons and alerts neighbouring cells. Some of the 
cytoplasmic PRRs (Rig-I, Mda-5, PKR) are depicted here and are referred to in the text (O. Haller et al. 
2006).
Sensing pathogens
Recognition  of  the  pathogen is  a  first  step  required  for  the  immune  response.  Antigen  sensing  is 
performed either by soluble factors, like antibodies or the complement system present in blood and 
mucus, or by receptors on the cell surface, in the cell cytoplasm or in phagocytic vesicles, formed after 
the pathogen has been engulfed. Cells not belonging to the immune system and cells of the innate 
immune  system  recognize  specific  molecules  by  pathogen  associated  molecular  pattern  (PAMP) 
recognition receptors (PRRs), that evolved to recognize a spectrum of pathogen molecules that are both 
essential for the pathogen i.e. cannot be lost to prevent immune system recognition, and shared by 
multiple species of pathogens. Such antigens can be displayed either on the surface of the pathogen, 
like peptidoglycan, lipopolysaccharide (LPS) and flagellin on the bacteria, mannans on the cell walls of 
fungi, envelope proteins of viruses, or the antigens can be sensed by the PRRs once the pathogen has  
been either lysed in a lysosome or, as in case of viruses, has been exposed in the host cytoplasm. 
Nucleic acids are a good example for such antigens – they are both essential to the pathogen and are 
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present in all pathogenic organisms. They are recognized by cytoplasmic sensors and by endosomal toll 
like receptors (TLRs) via their Leucine-Rich Repeat domains (LRR) (Fig. 2).  Both single-stranded (ss) 
and  double-stranded  (ds)  RNA and  also  DNA molecules  are  detected  in  order  to  cover  a  broad 
spectrum of pathogens. In endosomes, TLR-3 recognizes dsRNA, TLR-7 and -8 – ssRNA (TLR-8 is 
non-functional in mice),  and TLR-9 recognizes CpG DNA, i.e.  unmethylated CpG-repeats that are 
present in higher amount in bacteria than in animals. Once activated, Toll Like Receptors dimerize and 
associate with adapter  molecules  (MyD88/MAL, TRIF/TRAM) via the cytoplasmic TIR homology 
domain. Adapters then interact via their Death domain with downstream signalling kinases IRAK1/4, 
TAK1, IKK and TBK1 that lead to activation of AP1 and NFkB transcription factors and production of 
pro-inflammatory cytokines and to IRF3, IRF5 and IRF7 transcription factor activation that results in 
production of Type-I interferons (Fig. 3, reviewed in (West et al. 2006)).
Fig. 2. TLR4 as an example of Toll Like Receptor PRRs, contains the extracellular pathogen molecule 
sensing Leucine-Rich Repeat domain LRR and intracellular Toll/Interleukin-1 receptor domain (TIR) 
that  interacts  with  adapter  proteins  once  TLR is  activated  and dimerized.  LRR forms a  ring  like 
structure (shown right, structure based on human TLR3 and TLR2); modified from (Leulier & Lemaitre 
2008).
Cytoplasmic PRRs are useful to detect pathogens living inside of the cell and include RNA  and DNA 




as  a  response  to  infections  and  alert  both  the  immune  system  and  neighbouring  cells  about  the 
infection. Nucleotide-binding oligomerization domain (NOD)-like receptors, NLRs, contain a leucine-
rich repeat domain (LRR), just like TLRs, and a caspase activation and recruitment domain, CARD, 
that is necessary for the recruitment of downstream effectors that activate pro-inflammatory NF-kB 
signalling. Whereas NLRs recognize peptidoglycan components of Gram-positive and Gram-negative 
bacteria, bacterial DNA and some stress-related molecules, other cell proteins like RNA helicases Rig-I 
and Mda5, and DNA sensing proteins, like DAI, are important for anti-viral defense once viral nucleic 
acids have entered the cytoplasm and are not available for endosomal TLR recognition.  Rig-I and 
Mda5 are involved in recognition of double-stranded  RNA molecules and lead to the activation of 
TBK1/IKK-i  pathway  and  subsequent  pro-inflammatory  cytokine  production.  Cytoplasmic  DNA 
receptors like DAI, IFI16, RNA polymerase III  or AIM2 lead to  production of interferons via the 
TBK1-IRF3 pathway, activation of pro-inflammatory cytokines via NFkB and to production of IL1 and 
IL18 that leads to Th and B cell activation and to activation of macrophages via IFN-γ ((Akira et al. 
2006) (Proell et al. 2008) (Uematsu & Fujimoto 2010) (Unterholzner et al. 2010)).
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Fig.  3.  PAMP-receptors  lead  to  production  of  pro-inflammatory  cytokines,  including  interferons. 
Source: http://www.invivogen.com/ressource.php?ID=20
Interferons interfere with infections and with cell cycle
As previously  described,  interferons  (IFNs)  are  a  major  class  of  cytokines  that  are  induced upon 
infection. They serve as a protective armour that is worn against pathogens by different cells of the 
body, and as a bright banner that raises innate and adaptive immunity to arms. Most cells of the body 
induce  IFNs  via  intracellular PAMP  recognition  receptors,  whereas  specialized  IFN-producing 
plasmacytoid  dendritic  cells  (pDCs)  stimulate  induction  of  IFNs via  TLRs  (Fig.  1,  Fig.  3).  Once 
secreted, IFNs bind to neighbouring cells and signal via the Jak/Stat pathway. Upon IFN binding, its 
receptors dimerize and activate receptor-bound tyrosine kinases of the Jak family (Jak1, -2, -3 and 
Tyk2), that phosphorylate IFN receptors. This stimulates binding of signal transducer and activator of 
transcription molecules (STATs) via their SH2 domain to receptors and exposes STATs to Jak-mediated 
phosphorylation.  Once  phosphorylated,  STATs dimerize  and translocate  to  the  nucleus  in  order  to 
stimulate  interferon  responsive  genes  marked  by  specific  regulatory  sequences  ISRE (type  I  IFN 
targets) and GAS (type II IFN targets) in their enhancer regions (Fig. 4). 
Fig.  4.  Type I  and Type II  Interferon signalling  with 
STATs serving both  as  sensors  of  information  and as 
transcription factors; from (Schindler et al. 2007)
Interferons not only induce an anti-viral state in the cell but also activate its  pro-apoptotic program, 
possibly via altering p53 expression and via MAVS, common adapter of Rig-I and Mda5 localized on 
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the  mitochondrial  membrane.  IFNs have  also  non cell-autonomous functions that  lead  to  death  of 
infected cells - they stimulate cells of the innate and adaptive immune system, NK and cytotoxic T cells 
(CTLs),  to  kill  infected  cells.  Furthermore  CTLs  have  a  more  favourable  environment  for  clonal 
expansion in type I IFN presence and IFN-recieving DCs are more active in cross presentation (Stetson 
& Ruslan Medzhitov 2006).
Interferons were shown to alter the  cell cycle. Interferon treatment of transformed cells induces G0 
cycle arrest via IFN-induced genes like 2´,5´-OAS, OAS-dependent RNaseL, PKR and IRF1. OAS 
produces  short  2'-5'  phosphodiester-linked adenosine  chains  from ATP upon sensing  dsRNA.  This 
activates  endonuclease  RNase L that  cleaves  viral  RNA but  also  host  mRNA and rRNA, slowing 
translation  and,  as  a  result,  also  the  cell  cycle.  Produced  RNA fragments  are  sensed  again  by 
cytoplasmic sensors stimulating IFN production and also may trigger RNA damage stress response, 
leading to cell apoptosis (Silverman 2007). Interferons can inhibit cell cycle dependent kinases (Cdk-s) 
by induction of Cdk-inhibitors, e.g. Cdk inhibitor p21 is under transcriptional control of STAT1 (Chin 
et al. 1996). Furthermore, IFNs regulate tumor suppressors and oncogenes, e.g retinoblastoma tumor 
suppressor  (Rb)  protein  gets  activated  by  hypophosphorylation  and  c-myc  oncogene  synthesis  is 
inhibited.  IFNs can interfere with the IL2 signalling pathway and can inhibit  IL2-dependent clonal 
expansion of  T cells  (reviewed in  (Sangfelt  et  al.  2000)).  It  has  also been shown,  that  the newly 
discovered type III IFNs (IFN-λ, IFN-λ) also have an anti-proliferative effect on intestinal epithelial 
cell lines (Brand et al. 2005).
Type III Interferons and epithelia
Type I interferons can be produced by different cell types in response to PAMPs, but are synthesized in  
high amounts by plasmacytoid dendritic cells (Y.-J. Liu 2005). Production of type II interferon, IFN-γ, 
is restricted to NK, Th1 activated DCs and macrophages and has a pronounced macrophage-activating 
function  (Decker  et  al.  2002).  Type  III  IFNs,  also  called  IFN-λ or  IL28/29,  are  genetically  and 
structurally close to IL10. There are three isoforms of type III IFNs in humans, IFN-λ 1, 2 and 3, 
whereas in mice IFN-λ 1 is a pseudogene. Type III interferons bind to the receptor consisting of IL10R-
beta and IL28R alpha subunits but its downstream signalling pathway is shared with Type I interferons 
(Fig.  5)  –  activation  of  STAT1 and 2,  interaction  with  IRF9,  expression  of  antiviral  proteins  and 
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activation of MAPK kinase pathway. While having the same target genes, type I and type III IFNs have 
still been preserved throughout evolution. IFN-λ apparently plays a role in epithelial cells of mucosal 
surfaces, that respond stronger to it than other tissues due to higher IFN-λ receptor levels, and may 
provide an additional boost to these epithelial cells that are both the barrier against and the sensor of 
pathogens.  Type  III  IFNs  are  produced  by  epithelial  cells,  monocyte-derived  DCs,  and  pDCs  in 
response  to  the  same  stimuli  as  type  I  IFNs,  e.g.  virus  infections.  A study  shows  that  a  dsRNA 
analogue,  poly(I:C) can induce IFN-λ in  blood mononuclear cells  (Sheppard et  al.  2003),  possibly 
through TLR3.  Receptors to  IFN-λ are highly expressed in epithelia of lungs and intestine and in 
keratinocytes and make the host resistant to some RNA viruses (Sommereyns et al. 2008)(Mordstein et 
al.  2010)(Pulverer  et  al.  2010).  For  that  reason,  during  our  studies  we  also  investigated  whether 
intestinal and lung epithelial cells produce IFN-λ.
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Fig. 5. Three types of interferons use different receptors but converge on shared downstream signalling 
molecules. From (Takaoka & Yanai 2006).
Why investigate gut epithelial regeneration – Inflammatory Bowel Disease
Our primary goal was to find out  whether IFNs can alter intestinal epithelial cell proliferation. The 
main incentive for such research was that mutations in the IFN signalling pathway were linked in 
genetic  association  studies  to  the  development  of  Inflammatory  Bowel  Disease  (IBD)  in  humans 
(Anderson et al. 2009).
IBD  encompasses  two  different  diseases,  ulcerative  colitis  (UC)  and  Crohn's  Disease  (CD),  that 
although affecting different parts of the intestine, share some common features in their pathogenesis. 
UC primarily affects the mucosa in rectum, colon and caecum in a continuous fashion while CD is 
characterized  by  patchy,  transmural  tissue  destruction  in  the  whole  gastrointestinal  tract.  Growing 
incidence (Loftus 2004) of IBD led to increased scientific interest and as a result to important insights 
into what may trigger the development of the disease. Although there is low concordance of IBD in 
identical twins, arguing that diet/environment, microbiota and state of the host's immune system are 
important factors, genetic predisposition is still  regarded as one of the contributing factors of IBD. 
Prominent genes linked to IBD include: NOD2 (pathogen recognition), ATG16L1 (autophagy), Tyk2 , 
Stat3 and IRF5 (IFN-Jak/Stat signalling), MUC2 (mucus production), IL23 receptor and others (Franke 
et al. 2010). Some pathways are now being linked, e.g. in dendritic cells NOD and ATG16L may act  
together in order to display intracellular pathogens via class II MHC and to stimulate NFkB-mediated 
cytokine release (Ramjeet et al. 2010). 
Trigger events for IBD are the destruction of the protective epithelial layer accompanied by decrease in 
antimicrobial  proteins,  tight  junction  proteins,  Goblet  cells  and  over-stimulation  of  dendritic  cells 
(DCs) with bacterial antigens derived either from commensals or pathogens. The resulting uncontrolled 
inflammation of the submucosa leads to recruitment and activation of different T helper populations, 
NK and NKT cells,  monocytes  and macrophages  -  this  leads  to  further  epithelial  damage  and,  if 
untreated,  the patient  requires surgical  resection of the intestine in order  to remove affected tissue 
(reviewed in (Matricon et al. 2010). On early stages, IBD can be treated with immunosuppressants and 
anti-inflammatory drugs like sulfasalazine and corticosteroids, but 20% of patients are not treatable by 
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these drugs. Antibiotics and probiotics are given to patients in order to change host microbiota and 
potentially outcompete pathogens. Other drugs include anti-TNFa antibodies infliximab, adalimumab, 
that  not  only block TNF that  recruits  neutrophils,  macrophages  and lymphocytes,  but  also induce 
apoptosis in  lymphocytes and monocytes, block IFN-γ and GMCSF synthesis by T lymphocytes and 
restore  the gut  barrier  (Lawlor  & Moss 2009).  However,  30% of  patients  do not  respond to  such 
treatment and 50% of sensitive patients loose responsiveness after one year (Triantafillidis et al. 2011). 
Further studies are necessary to understand IBD and to develop new therapies.
The aberrant activation of the innate immune system, that is in close contact with the epithelial layer 
(Fig. 6), is believed to occur at early stages of IBD. Pathogen molecule receptors PRRs, are under close 
study in models of intestinal inflammation, because their activation leads to upregulation of various 
cytokines. There are different views on the role of TLRs in IBD development. TLR signalling has been 
implicated  in  the  release  of  a  proliferation-inducing  ligand  (APRIL)  and  thyminee  stromal 
lymphopoietin (TSLP) signalling molecules from IECs, which stimulate synthesis of protective IgA by 
B cells and prime DCs to stimulate regulatory T cells (reviewed in (Abreu 2010; Wells et al. 2011)). 
TLR-MyD88  signalling,  possibly  induced  by  commensal  bacteria,  stimulates  the  production  of 
cytoprotective IL6, TNF and KC-1 cytokines and inhibits the development of spontaneous colitis in 
IL10 deficient mice  (Rakoff-Nahoum et al. 2004). MyD88 signalling induced via TLR4 can lead to 
upregulation  of  EREG  and  AREG  that  activate  epidermal  growth  factor  receptor,  EGFR,  on  the 
epithelial cells and protect against colitis (Brandl et al. 2010). Apical stimulation of TLR9 in polarized 
cultured cells leads to production of protective IFN-β and TLR9 deficient mice are more susceptible to 
DSS-induced  colitis  (reviewed  in  (Clavel  & D.  Haller  2007)).  Further  studies  showed  that  TLR9 
stimulation leads to production of “anti-inflammatory” IFN-β via DNA-PK, IRF1, IRF7 and IRF8 and 
that IFN alpha receptor deficient mice (IFNAR KO) develop a more severe colitis upon DSS treatment. 
In order to find out what cell population provides this protective effect adoptive transfer (injection) of 
immune cells deficient in specific genes was performed. Wild type mice injected with IFNa/b receptor-
deficient macrophages and stimulated with TLR9 agonist were not protected against DSS-colitis like 
mice  that  received  wt  macrophages,  pointing  towards  the  involvement  of  macrophages  in  IBD 
development  (Katakura  et  al.  2005).  Stimulation  of  TLR3  via  subcutaneous  injection  of  double-
stranded RNA homologue, poly(I:C), into mice also led to protection against DSS-induced colitis and 
here IFNs were again regarded as negative regulators of colitis (Vijay-Kumar et al. 2007). Transfecting 
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poly(I:C) into intestinal epithelial cell lines leads to activation of cytoplasmic Rig-I and IPS1 nucleic 
acid sensors and to production of IFN-β (Hirata et al. 2010). Fukata et al. (2010) show, however, that 
activation of PRRs may lead to pathologies - TLR4 mediated signalling leads to a strong inflammatory 
response and to colitis-induced tumorigenesis. Local delivery of IFN-β, one of the target genes of TLR 
signalling,  by  IFN-β-producing  Lactobacilli  increases  sensitivity  to  DSS-induced  colitis  by 
upregulating TNF-alpha, IFN-γ, IL17A (McFarland et al. 2011). However, mice deficient in IRF1, a 
transcription  factor  responsible  for  IFN-β  and  IFN-β-inducible  genes  upregulation,  develop  worse 
DSS-induced  colitis  and  affected  cells  show  less  caspase  activity  and  antigen  presentation  genes 
(Mannick et al. 2005). This was unexpected, because IRF1 deficiency usually plays a protective role in 
other  inflammatory disease models  like diabetes,  encephalomyelitis  and arthritis.  It  seems that  the 
degree of TLR activation, sites of stimulation (systemic vs. local) and, possibly, the location of the TLR 
stimulus on the polarized epithelial cells may influence whether TLR signalling is protective or not. 
The exact role of IFNs in immune and non-immune system cells involved in IBD development still  
remains to be defined.
Fig. 6. Intestinal epithelial layer and immune system cells provide a barrier against commensal and 
pathogenic bacteria. IEL: intraepithelial lymphocyte. From (Abreu 2010)
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Mouse models are indispensable for studying disease development, associated risk factors and potential 
treatments. There are several models to induce IBD in mice. Disrupting epithelial layer by various 
chemicals may give us the answer whether the defects in the epithelium are causative in case of IBD or  
arise due to the already progressing disease. One of the commonly used experimental model utilizes 
dextran sulfate sodium (DSS), which is a polysaccharide that, if given to drinking water of mice, is 
destroying the mucus layer thus enabling bacteria to have direct contact with intestinal epithelial cells 
(IECs) and dendritic cells. DSS is used to start an acute inflammation reminiscent of UC and helps to  
investigate the role of the epithelium as a barrier as well as the involvement of the innate immune 
system in colitis  development.  Prolonged exposure to  DSS can also lead to chronic colitis  and, if 
combined with carcinogen azoxymethane, will lead to colon cancer development. In mice, prominent, 
but not unique, features of DSS-induced colitis include loss of body weight due to bloody diarrhea, 
shortening  of  the  colon,  high  levels  of  myeloperoxidase  (MPO)  i.e.  high  amounts  of  neutrophils 
recruited to affected tissues, increased mucosal permeability and increased inflammatory mediators like 
IL1b, IL6, IL12 and IFN-γ in the distal colon  (Yan et al.  2009). There are other mouse models of 
colitis, including haptenizing chemicals, total and tissue-specific gene knockout mice, adoptive transfer 
of T cell populations etc.  (Jurjus et al. 2004; A. Mizoguchi & E. Mizoguchi 2008; Wirtz & Neurath 
2007).
Intestinal epithelium and its stem cells
The  epithelial  barrier  of  the  intestine  has  high  turnover  rate  and  consists  of  various  types  of 
differentiated cells. Intestinal epithelial stem cells, ISCs, are located at the bottom of the crypts of the 
intestinal epithelium and divide asymmetrically to give rise to transient amplifying cells that proliferate 
and  differentiate  into  absorptive  enterocytes,  secretory  enteroendocrine  cells  and  mucus-producing 
Goblet cells. ISCs also give rise to Paneth cells, that produce antimirobial peptides and thus keep the 
crypt free of microbes. In search of localizing ISCs, several markers have been suggested, including 
musashi1, DCAMKL1, p-PTEN and others (Samuel et al. 2009). BrdU or H3-thymidine label retaining 
cells, LRCs, positioned at +4 position in the crypts, above Paneth cells, are considered to be quiescent 
stem cells and columnar based cells, CBCs, localized at the bottom of the crypt, are thought to be 
actively  dividing  stem  cells  (Fig.  7)  (Neal  et  al.  2010).  This  “zoned”  system  of  two  stem  cell 
populations is thought to protect the quiescent stem cells from accumulating mutations during division 
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and allowing them to reconstitute only the active stem cell population whereas the active stem cells can 
rapidly  regenerate  the  epithelial  layer  during injury  (L.  Li  & Clevers  2010).  A G-protein  coupled 
receptor, Lgr5, that lies downstream of Wnt signalling pathway, is now regarded as bona fide active 
ISC marker and the Lgr5+ cells reside at the crypt base (Barker et al. 2007). Attempts have been made 
to define the niche that provides Wnt/beta-catenin, EGFR and Delta/Notch proliferation signals for 
these stem cells, even myofibroblasts were suggested to play a role in the niche (Samuel et al. 2009). In 
2009  Sato et al. have defined the conditions for growth of ISCs in an artificial extracellular matrix, 
Matrigel, that contains laminin, collagen and several growth factors, with addition of Wnt, BMP and 
EGF stimuli. These cells formed organoids, i.e. clusters of crypts reminiscent of intestinal epithelium in 
mice, and ISC markers were retained in cells at the base of the crypt. Later, Paneth cells were found to 
provide  a  niche  for  the  ISCs  to  keep  their  stemness  via  Wnt,  EGF,  TGFb,  Dll4  (Notch  ligand)  
signalling pathways (T. Sato et al. 2010).
Fig. 7. Intestinal  epithelial  stem  cells  reside  
in crypts and give rise to transit amplifying cells  
that differentiate into enterocytes, enteroendocrine 
cells  and Goblet  cells.  +4 LRCs,  label  retaining  
cells at position 4 from the bottom of the crypt, are 
active  stem cells,  whereas  columnar  based  cells  
(CBCs)  are  quiescent  stem  cells.  Paneth  cells  
provide a niche for CBCs supplying the latter with 
Wnt,  Notch  and EGFR ligands.  From  (L.  Li  &  
Clevers 2010).
 
Gut regeneration after infection or after stress can be studied also in a genetically simpler model. Fruit 
fly Drosophila melanogaster provides a good model for the mammalian gastrointestinal tract – it has 
somewhat similar intestine compartmentalization and it possesses intestinal epithelial stem cells, that 
give  rise  to  undifferentiated  enteroblasts  that  differentiate  further  into  absorptive  enterocytes  and 
secretory enteroendocrine cells (Pitsouli et al. 2009). From studies done in D. melanogaster, it is known 
that upon infection or dietary stress, signalling from dying differentiated intestinal epithelial cells via 
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Jak/Stat pathway (in Drosophila: domeless receptor, hopscotch kinase and Stat92E as signal transducer) 
via stress cytokines Upd2 and Upd3 acts as a proliferation signal on ISCs and, together with Notch 
signalling, as a differentiation signal on enteroblasts (Jiang et al. 2009). EGF signalling has also been 
implicated in gut regeneration (Jiang et al. 2011) and TLR signalling may stimulate ISCs by inducing 
EGF receptor ligands ampiregulin and prostaglandin E2 (Abreu 2010). Such combined signalling leads 
to rapid regeneration of the gut epithelium within a few days, if bacteria or stress have been removed. It 
also correlates with mouse studies, where it has been shown that epithelial damage in DSS-inflicted 
colitis  stimulates the proliferation of ISCs.  We wanted to investigate, whether we can address the 
potential effect of IFNs on the proliferation of ISCs i.e. whether in mice they act similar to the Upd 
cytokines in the fruit fly.
Flu-Legionella Coinfections and Interferons
Because of our interest in the role of interferons during the infection of epithelia, we also conducted 
experiments  on  co-infecting  mouse  lungs  with  virus  and  bacterium  (Influenza  and  Legionella 
pneumoniae) to find out how flu infection can affect the course of the following Legionella-caused 
pneumonia. We also performed pilot experiments with intra-oral infections of mice with Gram-negative 
Salmonella and Gram-positive Listeria bacteria in order to find out whether these bacteria can induce 
Type III IFNs in gut epithelium.
Common flu-bacteria coinfections include such pathogens as S. pneumoniae, H. influenzae, various 
Staphylococcus and Streptococcus species (X.-Y. Wang et al. 2011). It has been noted, that, compared 
to influenza infection alone, combined flu and pneumonia leads to higher mortality, probably due to 
higher dissemination of bacteria if the lung epithelium is already damaged by virus, and by neutrophil 
mediated friendly fire, that leads to tissue destruction (DeLeo & Musser 2010). Possible mechanisms of 
mice being prone to following bacterial infections after the viral infection can also be desensitization 
of  macrophages'  Toll  like  receptors  (Didierlaurent  et  al.  2008),  downregulation  of  neutrophil 
chemoattractants (Shahangian et al. 2009), decrease of phagocytosis of alveolar macrophages via IFN-γ 
signalling  (K. Sun & Metzger 2008), decrease of IL12, a CTL and NK cell activator, released from 
DCs by viral haemagglutinin (Noone et al. 2005) etc. - the research in this field has to be continued to 
provide the whole picture of lung sensitization to bacterial infections by preceding exposure to viruses.
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Infections with Legionella bacterium can lead to pneumonia, that ranges from mild cough to respiratory 
failure  (Stout & V. L. Yu 1997). Legionella is a genus of Gram-negative bacteria that made its first 
appearance in 1976 when a large group of people contacted a previously unknown airborne bacterial 
pathogen that caused pneumonia. Legionella usually lives in amoeba and has evolved mechanisms to 
live in these phagocytic cells. Thus it is not surprising, that in animals it primarily infects phagocytic 
alveolar  macrophages.  It  contains Type 2 and Type 4 secretion systems and uses the latter,  called 
Dot/Icm, to inject its effector proteins from the phagosome into the host cells' cytoplasm. This leads to 
altered vesicle transport of the cell and prevents the phagosome from fusing with lysosomes, creating a 
protected niche for Legionella called Legionella-Containing Vacuole, LCV. Infected cells respond to 
infection  by  recognizing  Legionellas'  flagellin  via  cytoplasmic  Naip5  inflammasome,  by  sensing 
peptidoglycans via Nod1/2 and by detecting RNA via Rig-I and Mda5. This leads to proinflammatory 
NFkB signalling and to production of IFN-β ((Hubber & Roy 2010) (Newton et al. 2010) (Schuelein et 
al. 2011) (Vance 2010)).
It  has recently been shown, that flu infection leads to a general stress response and to increase of 
glucocorticoid serum levels that act as immunosuppressants. This leads to reduced IL6, IFN-γ and other 
chemokines  in  lung tissue  and to  lower  amount  of  infiltrating  cells  of  the  immune system to  the 
infected tissue. Complications with secondary pulmonary bacterial, e.g. Legionella, infection follow 
but also prevention of lethal immunopathology during such coinfections occurs (Jamieson et al. 2010). 
With this in mind, we wanted to investigate the effect of flu infection on subsequent Legionella-caused 
disease development, in particular concentrating on the IFN production by lung epithelial cells.
Aims summary
In this project we were interested in the role of IFNs in epithelial layers. Our main goal was to find out,  
whether IFNs can affect the regeneration of the epithelial layer by directly influencing the proliferation 
of the intestinal epithelial stem cells (ISCs). The aim of my thesis was to establish an in vitro method 
for studying the effect of IFN-β on primary intestinal epithelial cell proliferation and also to analyze a 
mouse  colon  epithelial  cell  line  for  responses  to  PRR stimulation.  We  conducted  experiments  on 
epithelial cell line to study its potential as a model of gut epithelium responses to pathogen molecules 
and infections. These studies are a part of a lager project that involves  in vivo studies of changes in 
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intestinal  epithelium, associated immune system and intestinal  microbiota  in  mice with chemically 
induced colitis. 
In addition, we wanted to investigate the role of IFNs during lung coinfections. We wanted to find out 
whether  there  are  indicative  levels  of  inflammatory  mediators  that  can  explain  worse  outcome of 
pulmonary coinfections as compared to infections with either virus or bacterium alone.
Methods overview - in vitro veritas
In order to model responses of gut epithelium to PRRs we first concentrated on stimulating the mouse 
colon epithelial carcinoma cell line, CMT-93, with different TLR ligands. To stimulate TLR4 we used 
lipopolysaccharide,  LPS,  a  molecule  containing  a  set  of  fatty  acid  chains,  an  oligosaccharide  and 
glycan  polymers,  present  on  the  surface  of  Gram-negative  bacteria.  TLR3  was  stimulated  by 
polyinosilic-polycytidylic  acid,  poly(I:C),  a  double-stranded  RNA analogue  containing  a  strand  of 
cytidines paired to the strand of inosines, derivatives of adenines. To stimulate TLR9 we used type C 
CpG DNA that contains CpG repeats on the phosphorothioate backbone and is a potent inducer of IFN-
β in  pDC and B cells.  Unmethylated  CpG sequences  are  present  in  bacteria  and serve  as  PAMP, 
whereas CpG  in mammals are mostly methylated and are also present in relatively lower quantity  
because of CpG suppression,  the fact that upon spontaneous deamination, methylated cytidines are 
converted to thymines that can escape DNA-repair mechanisms and lead to point mutations (CpGs 
reviewed in (R Medzhitov 2001)). We used poly(deoxyadenylic-deoxythymidylic) acid poly(dA:dT) as 
a stimulant of intracellular DNA receptors DAI, AIM2, LRRFIP1, and also of dsRNA sensor Rig-I, 
once poly(dA:dT) is transcribed (Ablasser et al. 2009). We wanted to find out whether CMT-93 cells 
produce  Type  I  and  epithelium-specific  Type  III  interferons  in  response  to  TLR stimuli  and  also 
whether these IFNs have an effect on CMT-93 cells. To answer the first question, we monitored IFN-β 
and IFN-λ mRNA induction with qPCR upon TLR stimulation. To address responsiveness to IFNs, we 
observed  the  activating  phosphorylation  of  tyrosine  on  STAT1,  a  molecule  downstream  of  IFN 
receptors, upon incubating cells with IFNs. We also tested the effect of IFN-β on the proliferation rate 
of CMT-93.
To further investigate the question of IFN-β influence on epithelial cells, we isolated gut epithelial 
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cells, possibly containing intestinal epithelial stem cells, from intestine of either wild type or IFN-alpha 
receptor knockout mice and were monitoring their proliferation in vitro. We tested several isolation 
protocols, with and without enzymatic digestion, and considered different growth conditions. Finally 
we decided to grow intestinal epithelial cells after EDTA isolation without enzymatic digestion in soft 
agarose/agar culture (modified from Booth & O'Shea  (R. I. Freshney & M. G. Freshney 2002)). We 
seeded mostly single cell suspensions into agarose mixed with growth medium and cultured for more 
than a month in incubator – we expected that transiently amplifying cells and stem cells would form 
colonies (for a review about primary IEC culture: (Kaeffer 2002)).
Because primary IECs cultured without additional growth factors (unlike in (T. Sato et al. 2009)) were 
growing very slowly, we also devised a method for short-term culture of colonic epithelial cells. After 
trying different coatings of plates, we decided to grow EDTA-isolated crypts (modified from (Bartsch 
et al. 2004)) on extracellular matrix layer left on the dish after osmotic lysis of endothelial cells. This 
basement  membrane  contains  collagens  (mostly  Type  III  and  Type  I),  proteoglycans  (heparin, 
chondroitin  sulphate),  laminin,  fibronectin and elastin  (Gospodarowicz et  al.  1984).  Isolated  IECs 
attached and even spread out if seeded at lower densities to the endothelial basement membrane and 
experiments are planned to treat these cultures with IFNs to test for their effect on proliferation.
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CMT-93 cells respond to limited TLR stimuli
To investigate the potential of the mouse epithelial colon carcinoma cell line CMT-93 as a model for 
gut responses, these cells were cultured in presence of LPS to stimulate surface TLR4, poly(I:C) to 
stimulate endosomal TLR3 or Rig-I/Mda5, CpG to stimulate endosomal TLR9, and poly(dA:dT) to 
stimulate cytoplasmic DNA receptors and indirectly RNA receptors. Upregulation of IFN-β, antiviral 
MX2 and IFN-λ mRNA was used as the readout of this experiment. Poly(I:C) and poly(dA:dT) were 
applied on the cells with and without the transfection reagent that helps these chemicals to cross the 
cell membrane. CMT-93 cells responded strongly to transfected poly(I:C) – the upregulation of IFN-β 
and MX2 mRNA was seen 8h and 24h after transfection and upregulation of IFN-λ after 24h (Fig. 9). 
CMT-93 did not react to variable LPS concentrations and to CpG (Fig. 9). On protein level, CMT-93 
cells had increased levels of PStat1 after poly(I:C) transfection indicating the production of IFNs by 
these cells (Fig. 10, 11). When tested for responsiveness to IFNs, CMT-93 cells responded to IFN-γ and 
weaker to IFN-β both at 1h and 24h after stimulation (Fig. 11). Different transfection reagents were 
tested for poly(dA:dT) in order to be sure that it is transfected successfully into CMT-93 cells but still  
no response was observed (Fig. 11). 
Because  of  high  background  and  low signal  of  P-Stat1  after  poly(I:C)  stimulation,  we  sought  to 
monitor  also phosphorylation of Stat2,  that  is  involved in  Type I  IFN signalling.  We observed an 
unspecific background band in all CMT-93 samples and a weak specific P-Stat2 band only after IFN-β 
and poly(I:C) stimulation (Fig. 11). Other P-Stat2 detection antibodies from several suppliers did not 
show better detection (Fig. 12). 
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Fig. 9. CMT-93 cells were treated with different PAMPs to stimulate TLRs and cytoplasmic nucleic 
acid receptors. CMT-93 produce IFN-β, IFN-λ and MX2 mRNA only in response to poly(I:C), that 
stimulates TLR3 and Mda5. Increase in IFN-β and MX2 may be explained by the autocrine IFN-β 
loop. Conc.: poly(I:C): 5µg/mL, poly(dA:dT): 5µg/mL, LPS: 100ng/mL, CpG: 10µg/mL (n=3 except 
poly dAdT: n=2).*: p=0.028, **: p=0.0035
Fig.  10.  CMT-93 cells  respond to 
IFN-β and to poly(I:C), as tested by 
WB against P-(Y701)Stat-1. IFN-β-
treated  bone  marrow-derived 
macrophages (BMDMs) were used 
as positive control, Erk as loading 
control.  Conc.:  IFN-β:  50U/mL, 
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Fig.  11.  CMT-93  react  to  IFN-γ  and 
weakly to IFN-β and poly(I:C), but not 
to  poly(dA:dT)  transfected  with 
Polyfect  or  Hiperfect  transfection 
reagents,  as  seen  by  phosphorylation 
of  Stat1.  Stat2  is  strongly 
phosphorylated  in  response  to  IFN-β 
1h  after  stimulation  and  also  in 
response  to  poly(I:C)  24h  after 
transfection.  An  unspecific  band  is 
seen  in  all  CMT-93  samples.  IFN-γ: 
0.5µg/mL,  IFN-β,  poly(I:C)  and 
poly(dA:dT) as in Fig. 10.
Fig.  12.  Detecting  P-Stat2  in 
CMT-93  cells:  none  of  the  P-
Stat2  antibodies  from  several 
suppliers   improved  signal-to-
noise ratio of WB. IFN-β-treated 
macrophages  were  used  as 
positive control, Stat2-KO MEFs 
as negative control.
CMT-93 do not respond to human IFN-λ
After observing the increase in IFN-λ mRNA levels after poly(I:C) stimulation, we wanted to find out 
whether CMT-93 cells are responsive to IFN-λ the same way as they respond to IFN-β. We decided to 
screen for P-Stat1, that is shared by both type I and type III Interferon signalling pathway. We have 
obtained IFN-λ (IL28B) of human origin and were interested whether  CMT-93 cells would react to it 
because Type I  interferons are regarded to be species-specific  (Sakaguchi  et  al.  1982) and type II 
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Interferon protein, IFN-γ, is only 40% homologous between mice and humans (Gray & Goeddel 1983). 
In our case, human IFN-λ stimulated only the human colon cell line LS174T but not mouse CMT-93, 
whereas  the  situation  was  reversed  for  mouse  IFN-β  (Fig  13A).  In  order  to  definitely  determine 
whether these cells are responsive to IFN-λ, it would be necessary to stimulate CMT-93 and LS174T 
also with mouse IFN-λ, make IFN-λ titrations and validate IFN-λ receptors in CMT-93. On mRNA 
level, CMT-93 cells also did not respond to IFN-λ (Fig. 13B).
Fig. 13. Interferons act in a species-specific fashion on intestinal epithelial cell lines. When analyzed 
for  Stat1  phosphorylation  (A),  mouse IFN-β stimulates  only  the  mouse-derived CMT-93 cell  line, 
human IFN-λ stimulates only the human-derived LS174T cell line. On mRNA level, no IFN-responsive 
MX2 gene upregulation is seen when CMT-93 cells are treated with human IFN-λ (B).
Testing for mucus production by CMT-93 cells
While further studying CMT-93 cells as model of colon epithelial cells, we tested whether CMT-93 
cells can produce mucus, that later can be harvested and used to grow intestinal bacteria (Dr. David 
Berrys' project). We tried washing the potential mucus layer with PBS from CMT-93 cells grown for 
several weeks without splitting. Then we analyzed proteins on SDS-PAGE gel and tried to see bands 
appearing  at  >200 kDa.  To stain  glycosylated  proteins,  including mucins,  we tried  oxidation  with 
periodic acid followed by Schiffs reagent staining accompanied by silver nitrate staining for better 
sensitivity.  This  protocol  failed  to  detect  any  specific  bands  (Fig.  14).  However,  at  the  time  of 
performing these experiments, we also did not have a positive control, so a problem with the staining 


































interest and sent to mass spectrometry analysis (15). We failed to detect mucin proteins and could not 
use CMT-93 for mucus production. 
Fig. 14. PAS-silver nitrate staining does not reveal mucin proteins. dXX: amount of days CMT-93 were 
in culture without splitting; s: cell culture medium supernatant; w: PBS wash of cell layer, M: weight  
marker
Fig. 15. Coomassie-stained SDS-PAGE gel depicting 
washes from confluent CMT93 cells grown on plate 
without splitting for 3 wk., bands marked with letters 
were sent to mass spectrometry analysis to search for 







I heat shock protein (HSP 90)
Epithelium of small intestine produces IFN-λ upon Listeria infection
After in vitro experiments with intestinal epithelial cell lines we wanted to find out whether Type III 
Interferons are upregulated also in response to bacterial infections  in vivo. First we infected CMT-93 
cells with Gram-negative Salmonella and Gram-positive Listeria bacteria and screened for IFN-β, MX2 
and IFN-λ upregulation (Fig. 16) and then we infected mice and isolated intestinal epithelial cells to 
screen for the same set of genes.
Salmonella are known to induce inflammatory NFkB activation in human epithelial cells in vitro by 
injecting  Sop proteins  into  cytoplasm bypassing  MyD88-dependent  TLR signalling  and  Caspase-1 
dependent inflammasome signalling (Bruno et al. 2009) although the recognition works differently in 
macrophages  (Franchi et al. 2009). Whether Salmonella can induce type III interferons is unknown. 
Listeria recognition is also not completely understood. Once the bacteria are in the cytoplasm, they 
activate TBK1 and lead to IFN-β production via IRF3 together with RNA helicase DDX3X stimulation 
(Soulat et al. 2008), but there is little data on induction of IFN-λ by Listeria. Recently, Lebreton et al., 
(2011) showed that in LoVo intestinal epithelial cell line IFN-λ is strongly upregulated as a response to 
infection with Listeria.
Fig. 16. CMT-93 cells upregulate IFN-β, 
MX2 and  IFN-λ  in  response  to  Listeria 
(MOI 100)  but  not  to  Salmonella  (MOI 
10) infection.
We have found out, that epithelial cells from small intestine respond to Listeria infections when tested 
for  IFN-β,  IFN-λ  and  MX2  mRNA (Fig.  17).  Infection  with  Salmonella  did  not  lead  to  strong 























 Viral-bacterial coinfections in lungs
As mentioned in  the  introduction,  viral  pulmonary  infections  may lead  to  increased  sensitivity  of 
patients towards bacterial infections. In order to test whether interferon production is induced during 
coinfection,  we  infected  mice  intra-nasally  with  influenza  virus  and  3  days  later  with  Legionella 
bacterium. We did not know whether the levels of IFNs will be lower in coinfected mice because of e.g. 
glucocorticoid release, damaged epithelium, impaired immune cell migration etc. or the levels will be 
higher because Legionella can activate further cytoplasmic PRRs e.g. Nod1/2 with its' PAMPs.
To our surprise we observed less IFN-β and IFN-λ mRNA in lung epithelial cells of coinfected mice as 
compared  to  cells  from influenza-only  infected  mice  (Fig.  19A).  We  did  not  see,  however,  such 
difference in total lung tissue or in lung lavage, that contains cells from alveolar fluid (Fig. 19B, C). 
Genes associated with tissue repair - Gcnt2 and Timp4 - are also not significantly higher in coinfected 
lungs (Fig. 19D, E). Future experiments, like determining the viral/bacterial load in the lungs in short 
intervals after infection, staining for viruses/bacteria in the lungs etc. might provide an explanation to 
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Fig. 18. IFN-λ is strongly upregulated only in 
the epithelial layer of the small intestine 24h 
after Listeria infection but not after 
Salmonella infection.
Fig. 17. Mouse epithelial layer responds to 
intraoral Listeria infection by upregulating IFN-β 
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Fig. 19. Relative to influenza infection alone, 
coinfection with influenza and Legionella leads 
to decreased production of inflammatory IFN-β 
and IFN-λ, anti-viral MX2, and, to lesser extent, 
tissue repair genes Mdk, Gcnt2 and Timp4. A: 
primary lung epithelial culture from infected mice 
(n=2); B: total lung tissue (n=1); C: lung lavage 
(cells washed out together with alveolar fluid) 
(IFN-β, IFN-λ data: n=2; MX2 data: n=1); tissue 
repair genes in lung epithelial cells (D, n=2) and 




Interferons influence cell proliferation
As mentioned earlier, destruction of gut epithelium leads to unrestricted contacts between intestinal 
microflora and intestinal epithelial and immune system cells. “Friendly fire” from recruited immune 
system cells inflicts further damage to surrounding tissue. Intestinal epithelial stem cells need to be 
activated in order to regenerate the protective epithelial barrier. We were interested in the effect of IFNs 
on the proliferation rate of intestinal epithelial cells because of in vivo studies of colitis in mice. Our 
hypothesis for different recovery rate of IFNAR KO mice from DSS-induced colitis when compared to 
wt mice is that IFNs may affect the proliferation rate of intestinal epithelial stem cells. In vivo studies 
of  epithelial  crypt  cell  proliferation  in  wt  and IFNAR mice,  using  BrDU label  incorporation  into 
cycling  cells  and  Ki67  proliferation  marker  staining,  did  not  show  significant  differences  in 
proliferation of colon epithelial cells during DSS-induced colitis (studies done by Dr. Isabella Rauch). 
There could be, however, subtle differences in proliferation that are not seen by these methods or that 
DSS effects just override the effects of IFNs on proliferation. However in other IFN-inducing situations 
(e.g. during Listeria infections etc.) the potential effect of IFNs on proliferation could be important. 
Thus we decided to test the effect of IFNs on CMT-93 cell line proliferation and also to isolate and 
culture mouse intestinal epithelial cells and observe IFN effect on their proliferation rate in vitro.
We found out, that IFN-β inhibits proliferation of CMT-93 cell line (Fig. 20) which is in concordance 
with similar studies, showing that IFNs have an anti-proliferative effect. We also tested whether IFN-β 
can penetrate the cells that are growing in soft agar system (Fig. 21) i.e. culture conditions used for 
primary intestinal epithelial cell growth. For this, IFN-β solution was applied to the wells with CMT-93 
and primary epithelial cells, both grown in soft agar, and after a period of time mRNA was harvested 
using Trizol chemical, that uses the phenol/chloroform RNA extraction principle. RNA quantity was 
too low from wells with primary intestinal epithelial cells, that is why only CMT-93 data are presented.  
We found out that CMT-93 cells were responsive to IFN-β and poly(I:C) treatment when grown in soft 
agar (Fig. 22). 
30
Fig.  20.  Type  I  IFNs  inhibit  the 
growth of CMT-93 cells  as tested 
by MTS proliferation assay.  Cells 
were  seeded  in  different 
concentrations  in  order  to  avoid 
false  negative  results  caused  by 
seeding the  cells  too  densely  and 
inhibiting their proliferation due to 
contact  inhibition.  EGF  was  used 
as   positive control.
Fig. 21. Schematics of the soft agar system used 
for growing intestinal epithelial  cells. Every well 
of  a  24-well  plate  is  covered  with  agar/DMEM 
mixture, left to solidify, then covered with a single 
cell  suspension  mixed  with  warm  agarose  and 
DMEM. Stimulation at d0: stimulus added to top 
layer of agarose, later stimulations: stimulus added in DMEM on top of agarose at the specified time.  
The  top  layer  was  always  kept  moist  by  applying  250µL DMEM/2.5% FCS,  adding  more  when 
necessary.
Fig. 22. CMT-93 cells remain responsive 
to  IFN-β  and  poly(I:C)  even  when 
cultured  in  agarose  –  the  expression  of 
IFN-β mRNA increases  after  stimulation 
with  IFN-β  for  24h.  Conc.:  IFN-β: 
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When seeding primary intestinal epithelial cells, we took care to seed single cell suspensions so that the 
colonies grown after the incubation period were definitely in vitro grown colonies and not groups of 
cells left undissociated after isolation procedure. We have monitored the size of colonies from primary 
epithelial cells over time in order to ensure that the colonies grow. We observed a decrease of smaller  
and an increase of larger colonies with ongoing cultivation (Fig. 23).
Fig. 23. Primary epithelial  cells 
grow  in  vitro  in  soft  agar. 
Colony  growth  assessed  by 
measuring colony size at day 42-
70 after isolation.
Next we isolated mouse intestinal epithelial cells from the small intestine and colon of wt C57BL/6 
mice  and  IFNAR1 KO  mice  as  single  cells  and  seeded  them into  soft  agar.  After  4  months  we 
determined the colony amount and colony size in order to find out whether the stem cell amount and 
the  stem cell  activity  are  different  between  wt  and  IFNAR KO mice.  There  was  no  pronounced 
difference  in  the  colony  count  between  the  wild  type  and  the  knockout  mice  when  the  single 
measurements were pooled (Fig. 24).
When the colony sizes were analyzed, no significant differences were found between colonies from wt 
and IFNAR KO intestinal epithelial cells. Nevertheless, there is a trend of IFNAR KO colonies from 
small intestine to be smaller (Fig. 25A, mice pairs 1-3) and from colons to be bigger (Fig. 25B). When 
tested for sensitivity to IFN-β at different stages, we expected IFNAR KO primary cells not to respond 
– we have seen non-significant differences between cells treated with IFN-β immediately after seeding, 
2 weeks after seeding or in absence of IFN-β treatment both in wt and IFNAR KO cells. The only 
significant difference was observed between non-treated IFNAR KO cells and wt cells treated 2 weeks 





























Fig. 24. Numbers of colonies of intestinal epithelial cells from small intestine (A) and colon (B) do not  
differ between wt C57BL/6 mice and IFNAR KO mice. Groups of cells isolated and seeded on the 
same day are joined by lines.
Fig. 25. Intestinal epithelial cells isolated from the small intestine of wt mice form, in general, bigger 
colonies (except of the 4th pair of mice) than colonies from IFNAR KO mice (A), although the situation 




Fig. 26. Primary intestinal epithelial cell colonies 
grown  under  IFN-β  stimulus.  IFN-β  was  added 
either during seeding (d0) or 2 weeks after seeding 
(d14). There is a significant difference (p>0.05) in 
colony size between untreated IFNAR1 -/- and wt 
C57BL/6 cells  treated with  IFN-β 2 weeks after 
seeding. (n=2)
Because of slow cell growth we tried to determine whether colonies that we see after some period in 
soft  agar culture still  contain living cells. Trypan blue (TB) staining did not show clearly positive 
(dead) and negative (alive) cells  even in CMT-93 cell  colonies. This may be explained by several 
technical problems: concentrated TB stain was hard to remove from the agarose block, whereas too 
diluted TB did not give strong staining. Furthermore, because the agarose block is optically denser than 
fluid medium and is also uneven, differential contrast microscopy did not work on our samples. That is 
why we decided  to  try  fluorescent  staining.  We picked ethidium bromide  as  the  stain  that  would 
penetrate  dead  cells  and  stain  DNA,  whereas  acridin  orange  (AO)  would  counterstain  live  cells. 
Enzymatic conversion of fluorescin diacetate was a second method of choice for staining live cells. In 
CMT-93 colonies clear distinction between live and dead cells was possible but colonies from primary 
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Fig. 27. Viability staining tested to establish whether colonies from primary intestinal epithelial cells 
are viable. CMT-93 cells were used as control cells (A-F). Both acridine orange (AO) and enzymatic 
fluorescein diacetate (FDA) stain live cells, whereas ethidium bromide (EtBr) that stains dead cells. 
Staining of primary intestinal epithelial cells (G-O) gave inconclusive results.
We have also devised a method for culturing epithelial cells from colonic crypts for short period of 
time. After we managed to isolate relatively intact crypts using chelating EDTA, we tested several 
conditions  in  order  to  keep  cells  adherent.  We tried  non-coated  tissue  treated,  gelatin  coated  and 
collagen coated plates and in all cases the isolated primary intestinal epithelial cells failed to attach. 
Then we tried to seed cells on a feeder cell layer consisting of mitomycin treated i.e. non-proliferating 
mouse  embryonic  fibroblasts  (MEFs)  (E  Michalska  2007) but  encountered  the  problem of  MEFs 
detaching from the plate. Finally, we plated CMT-93, MEF and endothelial cells and, after reaching a 
confluent layer, osmotically lysed the cells with ammonium hydroxide in order to obtain plates covered 
with extracellular matrix (ECM) components left by these cells. Only endothelial cells lysed nicely and 
left  ECM to which primary intestinal epithelial  cells  were able to attach (Fig 28C).  In the future,  
experiments may be performed on these short-term cultures including stimulation with PRR agonists, 
proliferation studies in presence of IFNs etc.
Fig.  28.  Gut  epithelial  cells  of  different  shape.  In  soft  agar,  CMT-93 carcinoma cells  form round 
colonies (A), whereas primary intestinal epithelial cells often form crypt-like colonies (B). Staining 
with trypan blue was performed in an attempt to check the viability of cells in colonies. Colon crypt 
cells grown on ECM from endothelial cells adhere and spread if seeded not too densely (C).
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Discussion
One of our starting questions was whether we can simulate the responses of intestinal epithelial cells to 
pathogens and their molecules in vitro in order to better understand the gut defence mechanisms against 
infection.  We  were  interested  to  find  out  how  the  cells  react  to  the  microbiota,  what  pathogen 
associated molecular patterns are recognized and what the responses are that help the epithelial layer in 
fighting off pathogenic microbes. 
First we dissected the responses of immortalized CMT-93 intestinal epithelial cells to several PAMPs. 
We found out that these cells respond by upregulation of IFN-β, IFN-λ and MX2 to poly(I:C), a dsRNA 
analogue and a strong TLR3 stimulant. The cells did not respond to other nucleic acid-derived stimuli,  
like poly(dA:dT) and CpG, no matter  whether  the  transfection reagent  was used or not.  Applying 
poly(I:C) without the transfection reagent also did not lead to upregulation of IFN-β, IFN-λ and MX2 
(not shown). The transfection procedure leads to poly(I:C) being located inside of the cytoplasm, that 
may lead to Mda5-mediated IFN production  (Kato et al. 2006). Additionally, it has been shown for 
human intestinal epithelial cells, that  transfected poly(I:C) leads to upregulation of IFN-β not via the 
TLR3 but via the RigI pathway (Hirata et al. 2011). Thus CMT-93 cells' TLR3 signalling may not play 
the role in responses to poly(I:C) – to test this hypothesis we would need to either knock down TLR3 
or to inhibit its downstream signalling pathway, e.g. to block TRIF adapter protein. 
Unresponsiveness to CpG was unexpected because intestinal epithelial cells should express TLR9 and 
upon CpG stimulation should activate NFkB pathway, although the studies showing such findings were 
performed on polarized IECs (Takeshita & Ishii 2008). It was also shown that TLR9 is expressed on 
the surface of mouse intestinal epithelial cells and on human colon epithelial HT-29 cells (Ewaschuk et 
al. 2007), that is why we first decided to stimulate cells with CpG without transfection. Maybe, the 
spatial localization of TLR9 is important for responses to CpG, but we have not grown CMT-93 cells in 
polarizing conditions (growing polarized CMT-93 described in: Iliev et al. 2009).
Testing several different concentrations of CpG, poly(dA:dT) and LPS did not lead to upregulation of 
IFN-β, MX2 and IFN-λ mRNA.  We wondered whether  CMT-93 express  needed TLRs – we have 
performed qPCR check for TLR3, and 9  and we obtained a weak signal (not shown) for these PRRs. 
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We were surprised to see absence of IFN and MX2 upregulation after treatment with LPS even at very 
high  concentrations.  Intestinal  epithelial  cells  should  be  sensitive  towards  this  major  bacterial 
component. Studies in human intestinal epithelial cell lines show that stimulation of TLR4 leads to 
upregulation of epiregulin, EGFR stimulant,  that leads to increased proliferation  (Hsu et al.  2010). 
Simulating CMT-93 cells with LPS leads also to MAPK phosphorylation within 5 minutes after LPS is 
applied (Cario et al. 2000). We were mostly interested in the response of cells to IFNs, but in the future 
proliferation studies on CMT-93 cells treated with various PRR stimuli can be performed. If there is a 
response in proliferation rate, then in CMT-93 cells there might be a defect on the path between TLR 
and IRFs, the transcription factors for interferons, but the other signalling pathways might be intact.
During our screens for IFN-λ upregulation we have noticed the presence of two peaks in the melting 
curves of qPCR products probably meaning that we were detecting two IFN-λ isoforms: IL28A and 
IL28B i.e. IFN-λ 2/3. An interesting detail of responsiveness of CMT-93 cells to PAMPs was that one 
of the isoforms prevailed if cells were stimulated with poly(I:C). However, we were not able to verify it 
with isoform-specific primers due to low signal from qPCR analysis, apparently due to low efficiency 
of these primers.
The finding that interferon beta inhibited cell proliferation of the CMT-93 cell line was an expected 
result as it was shown before that antiviral activities of interferons impair translation and slow down 
the cell cycle (Brand et al. 2005), (Hoffmann et al. 2011), (Sangfelt et al. 2000). However, the effect of 
IFNs on the  proliferation  of  the  primary  intestinal  epithelial  cells  and  especially  on  the  intestinal 
epithelial stem cells was harder to determine. At first, we had to establish a protocol that would yield 
single cell suspensions. Digestion of intestinal tissue with collagenase, dispase or pancreatin did not 
produce desired single cell suspensions. Addition of DNase I, that should aid in dissolving cell clumps 
held by DNA aggregates also did not improve the isolation. Treating intestinal tissue with chelating 
EDTA solution yielded the suspension of single cells and small clumps of cells, the latter were filtered 
out through cotton wool. This rather rough treatment of the primary intestinal cells, and also wash of 
tissue with anti-fungal amphothericin in order to combat contamination, may have lead to low colony 
growth efficiency of the primary cells. The other factors leading to such low efficiency might have 
been: the absence of defined growth factors, except 2.5% serum in the medium; fluctuating (20-70%) 
viability of freshly isolated cells; absence of extracellular matrix components, unlike in Matrigel. We 
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have also tried to culture the cells in agarose gels of different strength, in order to have gel tensile 
forces similar to Matrigel, used for culturing such cells in vitro.  T. Sato et al. (2010) found out that 
Paneth  cells  provide the  niche  for  intestinal  epithelial  stem cells.  After  seeding cell  doublets,  that 
contained Lgr5+ ISCs and Paneth cells, into Matrigel, the authors have observed drastic increase in 
colony formation efficiency as compared to seeding Lgr5+ single cells only. Also, when sorted Paneth 
cells and ISCs were mixed together, both cell types were forming contacts with each other and were 
effectively forming the colonies. We incubated the single cell suspension in liquid medium prior to 
seeding them into agarose in attempt to obtain cell pairs, that potentially might contain a Paneth cell 
and an ISC. These experiments however failed to increase the number of colonies. The low efficiency 
and long incubation time needed for the colonies to grow make the soft agar method not well suited for  
studying intestinal epithelial cell growth. 
The colonies that we have grown in soft agar did often resemble the cylindrical shape of intestinal 
crypts, but we did not develop a method for staining cells in soft agar with e.g. epithelial cell marker 
antibody in order to confirm their identity. Future experiments may include confirming the intestinal 
epithelial stem cell character of the cells after long-term growth in soft agar by running a PCR for Lgr5 
gene, that is a recognized marker for such cells. After the colonies were formed, we expected to see 
clearly two groups of colonies: smaller colonies formed by transiently amplifying cells, that have a 
limited proliferation potential and larger colonies formed by bona fide intestinal epithelial stem cells, 
but this was not observed. Probably, due to lack of specific growth factors in soft agar system, only the 
ISCs or TA cells are able to grow.
A defining experiment of testing whether IFNs influence the proliferation rate was when we treated 
both wt and IFNAR1 KO primary epithelial cells with IFN-β and monitored colony growth. There was 
only a small difference between non-treated IFNAR1-/- and IFN-treated wt cells in colony size even 
though we knew that  IFN-β can penetrate  the soft  agar.  Wt cells  formed bigger  colonies that  can 
suggest proliferatory function of Type I IFNs in intestinal epithelial layer. An important test lacks here: 
after  finding  out  that  IFNs  have  anti-proliferative  effect  on  CMT-93  cells  in  standard  growth 
conditions, we should have tested the effect of IFNs on proliferation of these cells in soft agar. 
The epithelium of the small intestine and colon differs in several ways: there are no protruding villi in 
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the colon, the colonic mucus consists of two layers, bacterial composition is different suggesting that 
there might be differences in epithelium-bacteria interactions (Wells et al. 2011). Based on our results 
there is a clear trend of untreated IFNAR KO cells forming larger colonies when isolated from colon,  
and forming smaller colonies when isolated from small intestine when compared to wt cells. This  may 
further highlight the differences between colonic and small intestinal epithelium.
Based on our results of IECs growth in soft agar, the different recovery of IFNAR KO mice from DSS-
induced  colitis  when  compared  to  wt  C57Bl/6  mice  is,  possibly,  not  entirely  explained  by  small 
differences in proliferation rates of ISCs. An alternative explanation of different recovery rates could be 
altered recruitment and/or activity of the cells of the immune system at the damaged site. To rule out 
the involvement of immune cells in the recovery process, a tissue-specific IFNAR knock-out would be 
needed, e.g. using a floxed IFNAR gene and a Cre recombinase under the control of Lgr5 promoter. 
Also  it  would  be  beneficial  to  use  mouse  infection  models  where  the  epithelium of  either  small 
intestine or colon is affected. Maybe Listeria can play a role of such pathogens as we show that they 
induce IFNs mostly in the small intestine.
Less tissue destruction during colitis might lead to better recovery, although the histology data from Dr. 
Isabella Rauch show that the destruction of the tissue is similar at the point where the mice are most 
affected by DSS administration. And the data from Drosophila (Jiang et al. 2009) clearly argue for the 
involvement of Jak/Stat pathway in the stimulation of epithelial layer regeneration. The question of 
influence of IFNs on the ISC proliferation in mice remains to be answered.
In the search of an alternative approach, we have developed a short term culturing method of intestinal 
epithelial cells on ECM left by endothelial cells. One of the possible future experiments could be to 
apply IFNs onto such cultures and watch for an effect in proliferation, although we still have not tested 
whether  the  cells  in  such  culture  conditions  actually  proliferate.  Furthermore,  we  could  test  the 
sensitivity of such primary cells towards PAMPs that we have tested on CMT-93 cells and correlate the 
results with already known cell line data and in vivo data. In addition, testing for epithelial antigens 
with fluorescent antibody staining is more simple that in soft agar system. The developed method might 
provide  some  valuable  insights  into  relatively  freshly  isolated  cells  and  allows  time  for  cell 
manipulation.
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The data from intestinal cells of mice infected with bacterial pathogens suggest higher expression of 
Type I IFNs 24h after infection with highest expression in small intestine epithelial cells from Listeria 
infected mice. Type III IFN was strongly upregulated only in Listeria infection and not in Salmonella 
infection. Low inducibility by Salmonella infection corroborates findings of (Salzman et al. 1998) that 
observed IFN-β upregulation in Salmonella infected mice only with pre-treatment of cells with IL1 or 
LPS. It would be interesting to discover why Listeria have stronger effect on the upregulation of IFN-λ 
when compared to Salmonella and also to make a comparison with bona fide inducers of IFNs, i.e. 
viruses.
Because we used different amounts of bacteria for infections, we might have also monitored a gene that 
is more characteristic for anti-bacterial responses then IFN, e.g. iNOS – this would give us a relative 
measure for the activation of IECs by these two different bacteria. Other genes could have also been 
monitored - (Eckmann et al. 2000) shows for human IEC lines that upon Salmonella infection G-CSF, 
MIP2-alpha, IRF1 and other genes are strongly upregulated as early as 3h after infection. We have 
noticed from the CMT-93 studies (not shown) that the cells respond with different strength to same 
MOI of Salmonella and Listeria.
Upregulation  of  IFN-λ  upon  bacterial  infection  in  intestinal  epithelial  cells  points  towards  the 
importance of this  IFN class in the epithelial  cells  during the bacterial  infection.  It  would be also 
interesting  to  screen  for  IFN-λ  upregulation  in  associated  immune  cells.  Performing  infections  in 
ligated intestinal loop model may be considered if more controlled infection conditions are required for 
future experiments because of high variation between individual mouse infections.
Further finding supporting the importance of Type III interferons in epithelial cells comes from viral-
bacterial  coinfection  studies  in  lungs.  We  see  upregulation  of  both  type  I  and  III  IFN  upon 
(co-)infection with Influenza virus, however we see no upregulation of these genes in case of bacterial 
(Legionella) infection only. The picture is less clear when lung epithelial cells, total lung tissue and 
alveolar fluid (lavage) are tested for these genes. However, highest IFN-λ levels were observed in flu-
infected lung epithelial cells and lowest in Legionella-infected lung epithelial cells. This data combined 
with  the  results  from intestinal  infections  indicate  that  some  bacteria  (Listeria)  might,  as  viruses 
(Mordstein et al. 2010), induce IFN lambda in epithelial cells, whereas the other bacteria (Legionella) 
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do not induce IFN-λ.
From histology data (Dr. Amanda Jamieson) it is known that Influenza/Legionella coinfections lead to 
higher epithelial layer damage, but we have seen less upregulation of IFNs in coinfected mice. Our 
working hypothesis is that epithelial layer suffers larger destruction during coinfection (confirmed by 
histology done by my supervisor  Dr.  Amanda Jamieson)  and cannot  keep up with the  developing 
infection.  However,  the  levels  of  genes  linked to  tissue  remodelling,  Gcnt2  and  Timp4,  were  not 
significantly higher in coinfected lungs. Why the interferon level is lower in coinfected lungs remains 
an  open question.  One of  the possible  explanations  is  that  the mice  clear  up the  infections  faster 
because of a very strong immune response when Legionella is introduced into Influenza-infected mice 
but this has to be verified by histology and CFU/PFU data.
To sum up, we found out that IFNs can be induced by poly(I:C) in CMT-93 cells and that these cells are 
responsive to type I IFN and, in particular, IFN-β has an anti-proliferative effect on them. We have also 
found that type I and III IFNs are upregulated in mouse intestinal epithelial cells upon Listeria infection 
and in lungs upon Influenza infection and Influenza/Legionella coinfection. The data on IFNAR KO 
primary intestinal epithelial cell proliferation is not conclusive and at the moment we cannot link how 
exactly  mutations in  the Jak/Stat  signalling pathway might  contribute to  IBD development.  Future 
experiments are needed not only to study the epithelial homeostasis of the gut and the factors that 
influence it but also to provide clues whether IFNs can be used to treat IBD as there are conflicting 






10x buffer (Fermentas, +KCl, -MgCl2) 1.5µL
10mM dNTPs 0.3µL
primer fw (100µM)* 0.045µL
primer rev (100µM)* 0.045µL
SYBR green (in DMSO)** (freshly diluted 1:100 in H2O) 0.6µL
Taq Pol 0.12µL
DNA (1:3 dilution in H2O) 1.5µL
Temperature cycle:
• 1 cycle 95 degC 10 min
• 45 cycles 95 degC 15 sec → 60 degC 20 sec → 72 degC 20 sec
• 1 cycle 95 degC 1 min → 55 degC → melting curve 20 min → 95 degC 15 sec
*for 4µM primers (mixed) add 1µL of primer mix and only 8.39 µL H2O
**SYBR green is diluted 1:15 in DMSO and stored in dark at -20degC, then diluted 1:100 in water just 
before usage
Alternatively, mix 1µg RNA, primers (as above), bring to 7.5µL with H2O and add 2x SYBR Mix 
solution (Fermentas).
qPCR analysis
Melting curves are checked for consistency and compared to negative controls (H2O). Threshold for Ct 
values is set to appx. 3000. If values are deviating between duplicates for more than 1 cycle then they 
are not considered true. Following formula is used to calculate RNA levels:
RNA level: 2^(CtHPRT-Ctsample)








IFN-λ 2/3 fw: 5'-AGCTGCAGGCCTTCAAAAAG-3'
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IFN-λ 2/3 rev: 5'-TGGGAGTGAATGTGGCTCAG-3'
IL-28A fw: 5'-AAGGACCTGAGGTGCAGTTCC-3' (low efficiency)
IL-28A rev: 5'-GGCCAGGGCTGAGTCAGT-3' (low efficiency)
IL-28B fw: 5'-AGGACATGAGGTGCAGTTCCC-3' (low efficiency)
IL28B rev: 5'-GGTGGTCAGGGCTGAGTC-3'(low efficiency)
cDNA synthesis
• in PCR tube: put 1µg RNA and bring to 10µL with H2O
• add 1µL oligo-dT
• 5 min 70 degC (PCR machine)
• 5 min on ice
• add 4µL 5x RT buffer (Fermentas), 2µL 10mM dNTPs, 2µL H2O (make master mix for 
multiple rxns)
• 5 min 37 degC (PCR machine)
• add 1µL reverse transcriptase (RevertAid Fermentas)
• 1h 42 degC (PCR machine)
• 10 min 70 degC (PCR machine)
• store at -20 degC
RNA isolation (MN NucleoSpin RNA II kit, cells grown in 6-well plates)
• wash cells from medium with 2mL PBS
• apply 350µL RA1 buffer (complemented with 1% beta-Mercapto-Ethanol)
• if necessary, freeze in liquid N2 and store at -80 degC
• filter through violet collar insert tube by centrifuging 1 min 11,000 g
• mix f/t with same amount of 70% EtOH (not denatured), triturate x5
• apply liquid to blue collar insert tube, centrifuge 11,000 g 30 sec
• discard f/t, exchange collection tube, apply 350µL MDB buffer, centrifuge 11,000 g 1min
• discard f/t, apply 95µL DNase solution (diluted 1:10 in DNase buffer), incubate 15 min RT
• wash with 200µL RA2 (11,000 g 30 sec), change collection tube
• wash with 600µL RA3 (11,000 g 30 sec)
• wash with 250µL RA3 (11,000 g 2 min)
• elute RNA with 40µL RNase-free water (11,000g 1 min)
• if possible, use immediately for cDNA synthesis, store at -80 degC
RNA isolation (PureLink RNA Micro Kit Invitrogen)
• before isolation:
• add 1% of beta-Mercapto-Ethanol to Lysis buffer
• add EtOH to Wash buffer II as indicated
• dissolve DNase as indicated
• Carrier RNA: dissolve 1:100 in Lysis Buffer (final conc.: 5ng/µL), use 5µL of this solution 
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per isolation 
• [colonies were picked with a thin Pasteur pipette and collected in a drop of medium (isolation 
was not successful)]
• centrifuge cells 2 000 g 5 min
• discard s/n, resuspend pellet in 350 µL Lysis buffer (beta-Merc-EtOH added)
• add 5 µL of 5ng/µL Carrier RNA solution
• triturate
• homogenize by passing 5-10 times through G21 needle
• add 350 µL of 70% ethanol, mix thoroughly
• transfer 700 µL of cell lysate to column
• centrifuge 12 000 g 1 min RT, discard f/t
• add 350 µL Wash buffer I, centrifuge 12 000 g 1 min RT, discard f/t, replace collection tube
• mix 10 µL reconstituted DNase and 10 µL 2x DNase buffer, apply onto center of the column 
membrane, incubate 15 min RT
• wash with 350 µL Wash buffer I, centrifuge 12 000 g 15 sec RT
• wash with 500 µL Wash buffer II (ethanol added), centrifuge 12 000 g 15 sec RT
• repeat 2 previous steps
• centrifuge 12 000 g 1 min, discard collection tube and insert column into recovery tube
• apply 12 µL Rnase-free H2O, incubate 1 min RT, centrifuge 12 000 g 2 min RT
• store at -80 degC
• use 1:3 dilution for qPCR
Intestinal Epithelial Cells isoation (after Hornef, for RNA)
• isolate intestine
• rinse in ice-cold PBS
• use half of small intestine/colon for total tissue lysate:
• put tissue to ice-cold PBS
• vortex shortly, remove PBS
• add 700 µL RA1 buffer (MN kit)
• homogenize with Polytron homogenizer, put on ice for ~ 1 min for the foam to settle down
• transfer liquid homogenate to 1.5 mL tube
• store at -80 degC
• for epithelial layer, put other half of colon and representative parts of small intestine 
(beginning, middle part and ending, ~ 3 cm each, mixed together) into ice cold PBS
• remove PBS
• incubate in 30mM EDTA/PBS 10 min 37 degC
• shake vigorously
• remove s/n, add PBS
• centrifuge 1200 g 5 min, resuspend pellet in RA1 buffer (MN kit)
• store at -80 degC
Single cell isolation for soft agar
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• prepare:
• 2x DMEM medium: 5.352 g DMEM powder (Gibco), 400 µL 100x Pen/Strep, 4 mL 
100mM sodium pyruvate, 1.48 g NaHCO3 , 20 mL FCS, 200 µL 50mg/mL gentamycin; 
filter under sterile conditions
• 3mM EDTA/PBS, pH 7.4 (set with NaOH), add DTT to 0.5mM final concentration (50mL 
EDTA, 20µL of 1M DTT), filter
• Pen/Strep/Amphotericin sterilization solution: 40 mL PBS, 40 µL 1000x PenStrep, 800 µL 
of 250µg/mL amphotericin (Sigma)
• 1% agar in H2O, keep at 40 degC before mixing 1:1 with 2x medium
• 0.8% agarose in H2O, keep at 40 degC before mixing 1:1 with 2x medium
• pre-warm 1x- and 2x DMEM
• coat wells with 0.5% agar/DMEM: use 500µL per well of 24-well plate, coat 2 plates per 
mouse, use 2x6 wells for colon and 2x18 wells for small intestine (or You can coat during 
EDTA incubation step)
• put cotton wool into Pasteur pipettes (ca. 1 cm), do not press in very hard, autoclave in 
aluminum foil
• cut out small intestine and colon
• flush with ~ 10 mL PBS
• open intestines with scissors, cut into small pieces with scalpel
• wash 3x in 50 mL tubes with PBS (use 10 mL pipette)
• incubate for 5 min in sterilization solution (amphotericin)
• wash 2-3 times with PBS, decant all liquid, transfer to 15 mL tubes
• incubate in 8-10 mL 3mM EDTA 90 min RT under slow tilting
• [here You can coat wells with agar/DMEM]
• discard EDTA s/n from cells
• add 10-13 mL PBS and pass tissue several times through 10 mL pipette, transfer s/n to 50 mL 
tube, repeat in total 4 times pooling together s/n from every step (avoid air bubbles)
• centrifuge 400 rpm 1-2 min RT, carefully remove s/n
• resuspend in 5 mL PBS
• centrifuge 1 000 rpm 5 min
• remove s/n, resuspend in several mL EDTA (what is left from initial 50mL solution, distribute 
equally between intestines)
• pass through 40 µm strainer
• centrifuge 1 000 rpm 5 min
• resuspend in 5  mL pre-warmed DMEM
• pass gently through 18G and 21G needles (3 times each)
• pass through cotton wool-filled Pasteur pipette
• centrifuge 1 500 rpm 5 min and resuspend in small volume of 1xDMEM (small intestine – 500 
µL, colon – 100 µL)
• count cells using trypan blue (~ 1:20 dilution for colon, 1:80 (or higher) dilution for small 
intestine)
• bring small intestine cells from genotypes to same concentration, same with colon cells




• IFN treatment (x14 master mix, 12 wells):
• 875 000 cells
• 1750 µL minus cells volume (µL) of 2x DMEM (pre-warmed) (total volume of 
2xDMEM and cells has to be 1750 µL)
• 140 µL IFN-β (final concentration is 50 U/mL)
• 1750 µL 0.8% agarose (40 degC)
• no IFN treatment (x28 master mix, x24 wells)
• 1 750 000 cells
• 3500 µL minus cells volume (µL) of 2x DMEM (pre-warmed)
• 280 µL 1x DMEM
• 3500 µL 0.8% agarose (40 degC)
• colon (use half of amount if not enough cells)
• IFN treatment (x5 master mix, 4 wells):
• 312 500 cells
• 625 µL minus cells volume (µL) of 2x DMEM (pre-warmed)
• 50 µL IFN-β (final concentration is 50 U/mL)
• 625 µL 0.8% agarose (40 degC)
• no IFN treatment (x10 master mix, x8 wells)
• 625 000 cells
• 1250 µL minus cells volume (µL) of 2x DMEM (pre-warmed)
• 100 µL 1x DMEM
• 1250 µL 0.8% agarose (40 degC)
• 2 weeks after plating, add 200 µL of IFN-β solution where applicable and 1x DMEM to the rest
Lung epithelial cell (LEC) isolation
• coat tissue culture-treated 10cm dishes with anti- mouse CD45 and anti- mouse CD16/32
• add 50µg of each antibody per 5mL PBS per plate, observe sterile conditions
• seal with Parafilm and incubate 4 degC o/n
• coat 12 well plates with collagen type IV
• 1 mL of 1µg/mL collagen in PBS per well, store at 4 degC o/n
• before use, wash 2x with PBS
• prepare:
• sterile 0.9% NaCl, 20mL per mouse
• 1% (aq.) low melting agarose, autoclave and keep at 40 degC before use, 0.45 mL per 
mouse
• Dispase I, 1U/mL in PBS, 4mL per mouse
• 0.01% DNase I (0.01g/100mL) in DMEM, 7mL per mouse
• DMEM 10% FCS, pre-warm
• Ham's F12 complemented with:
• 15 mM Hepes
• 0.8 mM CaCl2
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• 0.25 % BSA
• 5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL sodium selenite (1884-1VL Sigma)
• 2% FCS
• ice
• euthanize mice by CO2
• open chest to have access to heart, lungs and trachea
• make small incision at top left of heart (right atrium)
• clear lungs from blood by injecting 20 mL NaCl solution to top right (left atrium) portion of the 
heart, lungs become white if perfusion performed correctly
• take a piece (~ 7 cm) of suture thread, make a knot around trachea but do not pull tight yet
• cut a small hole in upper part of trachea
• fill syringe with 1mL PBS, attach to needle fitted with silicon tube (~ 5-7 cm), insert silicon 
tube into trachea, pull the suture thread to prevent leakage (not too tight so that the tube is not 
closed), flush lungs with PBS in syringe (this will collect lung fluid and some cells/pathogens 
from the lung), keep the silicon tube in trachea
• transfer lavage fluid into 1.5 mL tube, centrifuge 1500 rpm 5 min, discard s/n, resuspend pellet 
in 350 µL RA1 buffer (MN kit), store at -80 degC
• fill lungs with 3 mL Dispase solution
• remove syringe, keep tube in trachea, fill lings with 0.45 mL agarose
• put ice on lungs for ~ 1-2 min until agarose solidifies
• cut the lungs out and put into 15 mL tube filled with rest of dispase, incubate 45 min RT
• pour 7mL DNase/DMEM into Petri dish
• take the lung out of tube, rip with forceps into small pieces, filter through 70 µm cell strainer 
into DNase/DMEM
• centrifuge cells 130 g 12 min 4 degC
• discard s/n, resuspend in 10 mL DMEM 10% FCS
• pour cells onto antibody-coated plates, incubate 2h 37 degC (panning)
• collect s/n and centrifuge it 130 g 12 min 4 degC
• remove s/n, resuspend in 10 mL Ham's F12 with additives, incubate 2h or o/n
• remove non-adherent cells, wash gently with PBS, apply RA1 (MN kit) lysis buffer, store RNA 
at -80 degC
Oral infection with Salmonella/Listeria
• take away food from mice for o/n 
• grow bacteria o/n (~ 3 mL, Salmonella in LB, Listeria in BHI)
• measure OD600 (OD6001=5*10^8 cfu/mL Salmonella and 1*10^9 cfu/mL Listeria (LO28) )
• infect with 100 µL bacteria suspension (gavage)
• 1-2 *10^9 cfu/mouse of Listeria
• 1 *10^6 cfu/mouse of Salmonella
• sacrifice mice when necessary, isolate RNA from intestines (total tissue or epithelial layer only)
MTT proliferation assay
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• cells seeded in 96-well plates and treated where necessary
• remove medium
• add 50 µL 10% MTT/medium solution
• incubate 3-4 h
• carefully aspirate medium
• add 50 or 100 µL of solvent solution
• stir gently
• measure specific absorption at 570 nm and background at 690 nm
MTS proliferation assay (Promega)
• thaw the reagent
• add 20 µL reagent per well containing cells in 100 µL medium
• incubate in incubator at 37 degC 5% CO2 for 1-4 h
• measure absorption at 490 nm
Protein detection via Western Blot
• separating gel: 
• 7.5% : 4 mL H2O, 2 mL 1.5M Tris HCl pH 8.8, 2 mL acrylamide, 160 µL 10% SDS, 24 µL 
20% APS, 24 µL TEMED
• 10% : 3.3 mL H2O, 2 mL 1.5M Tris HCl pH 8.8, 2.7 mL acrylamide, 160 µL 10% SDS, 24 
µL 20% APS, 24 µL TEMED
• 12% : 2.8 mL H2O, 2 mL 1.5M Tris HCl pH 8.8, 3.2 mL acrylamide, 160 µL 10% SDS, 24 
µL 20% APS, 24 µL TEMED
• stacking gel, 4%: 2.5 mL H2O, 1 mL 0.5M Tris HCl pH 6.8, 0.5 mL acrylamide, 80 µL 10% 
SDS, 12 µL 20% APS, 12 µL TEMED
• 5-20 µL of sample loaded (mix sample with 4x sample buffer and cook 5 min 95 degC, 
centrigufe 1 min max speed)
• 3 µL size marker loaded
• gel runs at 80V (running into separating gel), at 120V until necessary
• semi-dry blotting: anode (positive, down) | 6x 3MM Whatman in anode buffer 1 | 3x 3MM 
Whatman in Anode buffer 2 | membrane incubated in H2O | separating gel incubated in cathode 
buffer | 9x 3MM Whatman incubated in cathode buffer
• blotting running at 32 mA (fixed) 25 V 1.5h
• if necessary, colour with Ponceau red stain, decolorate with H2O, destain with TBST
• cut membrane if necessary
• block in 5% milk/PBS (3% BSA/PBS for phospho-specific antibodies)
• wash 3x 10 min TBST
• incubate with 1-ary antibody o/n 4 degC (antibody diluted in 2% BSA 0.05 % sodium azide)
• wash 3x 10 min TBST
• in the dark:
• incubate with 2-ary antibody (1:20 000 in TBST) for 30 min on shaker
• wash 3x 10 min TBST
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• scan on IR imager
• if necessary, strip membrane in order to incubate with an other 1-ary antibody:
• wash 3x 10 min TBST
• strip 5 min in stripping buffer
• wash with H2O
• scan on IR imager to check for background, if necessary, strip further
• wash 3x 10 min TBST
• block membrane again, proceed with 1-ary and 2-ary antibody staining as before
• 4x sample buffer: 0.25 M Tris pH 6.8, 20% glycerol, 1.6% SDS, 20% beta-mercaptoethanol
• SDS-PAGE running buffer: 0.25 M Tris, 1.92 M glycin, 1% SDS, pH 8.3
• Anode buffer 1: 0.3 M Tris, 20% methanol, pH 10.4
• Anode buffer 2: 2.5 mM Tris, 20% methanol, pH 10.4
• Cathode buffer: 0.04 M 6-aminocapronic acid, 20% methanol, 0.01% SDS
• stripping buffer: 200 mM Glycin pH 2.8, 150 mM NaCl, 0.5 % Tween 20, H2O
Colonic crypt cell isolation for short term culture
• seed bovine aorta derived endothelial cells CW1 (~ 100 000 cells per well) on collagen coated 
wells (1µg/mL), let them grow until confluency (1d)
• remove medium, wash several times with PBS, lyse cells with 5mM ammonia solution (observe 
swelling and destruction of cells under microscope) for several minutes, wash several times 
with H2O, store in cold PBS if necessary – this is ECM-coated plate
• sacrifice mouse, remove colon, rinse in ice-cold 0.91% NaCl
• close smaller end of Pasteur pipette with fire, insert Pasteur pipette into cap of 50mL tube
• fix one end of colon to small end of Pasteur pipette with thread, cut excess of thread away, 
invert and extend colon, fix other end with thread
• incubate in EDTA solution for 50 min 37 degC 100rpm
• scrape epithelial layer with scalpel into Petri dish, add 1 mL DMEM, count crypts under 
microscope, seed in up to 1000 crypts/1mL/well in ECM-coated plates, use DMEM 5 % 
FCS/PenStrep as medium
• next day, remove unattached cells, add 1 mL DMEM 5% FCS
• exchange half of medium every 2nd day
• EDTA solution: 1.5mM ETDA, 109 mM NaCl, 2.4 mM KCl, 1.5 mM KH2PO4, 4.3 mM 
Na2HPO4, 10 mM glucose, 5 mM glutamine
• medium for endothelial cells: 377.5mL DMEM high glucose, 100mL FCS, 5mL 100x non-
essential amino acids, 5mL 100mM (100x) sodium pyruvate, 12.5mL 1M HEPES
Salmonella/Listeria infection of CMT-93 cells
• inoculate single colony of Salmonella or Listeria into 3 mL LB or BHI respectively, grow o/n 
37 degC shaking
• Salmonella only: add 78 µL 5M NaCl to fresh 3 mL LB (final concentration 300 mM), add 75 
µL of Salmonella o/n culture, mix, incubate 3h 37 degC (no shaking) → this induces 
invasiveness
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• measure OD600 (OD6001=5*10^8 cfu/mL Salmonella and 1*10^9 cfu/mL Listeria (LO28) )
• Salmonella:
• wash bacteria 3x in pre-warmed DMEM, centrifuge at max speed 2 min in table top 
centrifuge
• add bacteria in total volume of 100 µL to cells
• spin bacteria onto CMT-93 cells by centrifuging at 1000 rpm 5 min
• incubate 1h 37 degC in incubator
• while cells are incubating, dilute bacterial inoculum and plate on LB plates to determine 
actual MOI (grow at 37 degC o/n)
• wash cells 1x with PBS, replace with medium containing 100 µg/mL gentamicin for 1.5-2 h 
to kill extracellular bacteria
• replace medium with antibiotics-free medium
• Listeria:
• apply necessary amount of Listeria
• incubate 2h with CMT 93 cells, remove s/n
• while cells are incubating, dilute bacterial inoculum and plate on BHI plates to determine 
actual MOI (grow at 37 degC o/n)
• add medium containing 50 µg/mL gentamicin, culture for 1h in incubator
• exchange medium to 10 10µg/mL containing medium
• LB: 10g Bacto-tryptone, 5g yeast extract, 10g NaCl, set pH to 7.5, add 15g agar, fill with H2O 
to 1L, autoclave
• BHI: 37 g/L BHI (brain heart infusion), 1% agar, aqueous solution
Protein lysis
• remove s/n from cells
• wash with PBS, remove s/n
• add 80 µL complemented Frackelton lysis buffer per well (6 well plate)
• scrape, transfer lysate to 1.5 mL tube
• store at -20 degC
• complementing Frackelton buffer:
• 50 µL protease inhibitor mix (“pill”, diluted in 5mL H2O according to manufacturer's 
protocol)
• 10 µL PMSF (100 mM in isopropanol)
• 10 µL sodium orthovanadate (10 mM in H2O)
• 1 µL DTT (1M in H2O)
• 1mL Frackelton buffer (10 mM Tris-HCl, 30 mM Na4P2O7, 50 mM NaCl, 50 mM NaF, 1% 
Triton X-100, pH 7.1, store at 4 degC), complement freshly
Coomassie staining
• fix SDS-PAGE gel in 40% ethanol 10% acetic acid aqueous fixing solution for 30 min
• wash 2x with H2O
• stain with Colloidal Coomassie (prepare freshly, 50 mL methanol, 200 mL Colloidal Coomassie 
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stock) for up to 3 h
• no need to destain
• fixing solution: 40% ethanol, 10% concentrated acetic acid, dissolved in H2O
• Colloidal Coomassie stock: 50g ammonium sulphate, 6 mL 85% phosphoric acid, 490 mL H2O, 
10 mL 5% Coomassie Brilliant Blue G-250 (aq.)
Mucus isolation
• plate CMT 93, wait until confluent
• collect s/n, wash cells with additional 3mL PBS, pool to s/n → s/n fraction
• add 5 mL PBS onto cells, pipette roughly (to potentially isolate the mucus layer), collect into 15 
mL tube, repeat 2 times pooling washes together → wash fraction
• add medium to CMT 93 cells and continue growing them (no splitting), collect s/n and wash 
fractions after 1-2-3 weeks again
• centrifuge fractions 1500 rpm 5 min RT, remove s/n
• add 50 µL of rehydration buffer
• transfer to 1.5 mL tube, store at -20 degC
• rehydration buffer: 8M urea, 2M thiourea, 4% CHAPS, 0.5% Triton X100, 0.005% bromphenol 
blue, H2O to 100 mL
Alcian blue staining
• grow cells on cover slips until they supposedly produce mucus layer
• remove medium
• fix cells with Carnoy's solution 10 min RT (60 % ethanol, 30% chloroform, 10% glacial acetic 
acid) 
• wash 2x PBS
• stain mucus polysaccharides and glycosaminoglycans with cationic 1% alcian blue 1h RT
• wash with H2O
• stain cell nuclei with kernechtrot 5-10 min RT
• wash with H2O
• embed and observe
• to prepare kernechtrot staining solution dissolve 0.1g kernechtrot in 100mL 5% boiling 
aluminium sulfate
Alcian-PAS staining
• stain with 1% alcian blue 30 min
• wash with 5% sodium tetraborate
• wash with H2O
• incubate with 0.5% periodic acid 10 min
• wash with H2O
• incubate with Schiff's reagent 30 min
• wah extensively with H2O
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• stain with hemalaun 30 sec
• wash with H2O
• dry and embed in Dako
Immunohistochemistry, FL antibodies
• grow cells on cover slips
• fix cells in 4% PFA 10-20 min RT
• wash 2x PBS
• permeabilize in 0.1% Triton X 100, 2-10 min RT
• wash 2x PBS
• block with 5% goat serum 30 min RT
• stain with 1:40 phalloidin (for actin) 40 min RT
• stain with primary antibodies of choice: 
• anti-E-cadherin, mouse, 1:50 in 2% BSA
• pan-Cytokeratin-FITC, 1:50 in 2% BSA
• wash 1x PBS
• stain with secondary antibody:
• anti-mouse 488, 1:1000 in 5% normal goat serum, 2h RT
• wash 1x PBS
• stain with 25 µL 1:1000 Dapi for few seconds
• wash 2x PBS
• wash 1x H2O
• mount on DAKO mounting medium on slide
• let dry o/n
• store at 4 degC
Probe preparation for Mass Spectrometry
• wear gloves & change them frequently to avoid keratin contamination
• cut out gel pieces with band of interest
• add 100 µL ABC buffer, 80 µL acetonitril (ACN) solution and shake 15 min 900 rpm 20 degC
• remove fluid, repeat if gel piece still has some colour
• remove s/n, add 80 µL ACN, shake 5 min 900 rpm 20 degC
• remove ACN
• dry in vacuum centrifuge 10 min RT
• add 200 µL 10 mM DTT (15mg/10mL in ABC buffer), shake 30 min 900 rpm 56 degC
• remove s/n, add 80 µL ACN, shake 5 min 900 rpm 20 degC
• remove ACN
• add 100 µL iodo acetamide (10mg/mL in ABC buffer), incubate in dark 20 min RT, no shaking
• remove s/n
• wash 3x with 200 µL ABC buffer (10 min 900 rpm), remove s/n
• add 80 µL ACN, shake 5-10 min 900 rpm 20 degC
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• remove s/n, remove rest in vacuum centrifuge 10 min RT
• make Trypsin Gold working dilution (12.5 ng/µL) in 70 µL ABC buffer
• add 5-10 µL of Trypsin Gold soluiton onto every gel piece
• 5 min on ice, gel absorbs trypsin
• remove s/n if any
• cover gel piece with ABC buffer to avoid drying-out
• o/n digestion 37 degC (12-16 h)
• stop digestion with 10% trifluoracetic acid (TFA) (final concentration should be 1% TFA)
• sonicate 10 min (peptides go to solution, 1st extraction), collect fluid into small PCR tube
• add 10 µL 0.1% TFA to gel pieces, sonicate 10 min (2nd extraction), pool with 1st extraction
• freeze at -80 degC
• ABC buffer: 50 mM ammonium bicarbonate (198 mg in 50 mL MQ H2O)
CMT-93 stimulation (poly-IC, poly-dAdT, IFN-γ, IFN-β,   LPS, CpG) , calculations per well of 6-well   
plate
• poly-IC:
• 10 µg pI:C + 1 mL DMEM + 3 µL Hiperfect (mix in this order) → 10 min RT
• remove s/n from cells, apply this solution
• 6h later add 1mL DMEM 20% FCS
• poly dAdT:
• 10 µg pdA:dT + 3 µL Polyfect → 10 min RT → + 1 mL DMEM 10% FCS
• remove s/n from cells, apply this solution
• 6h later add 1 mL DMEM 10% FCS
• IFN-γ: add directly 1µg/well
• IFN-β: remove 400 µL s/n, add 5x IFN-β solution (5x stock is 250U/mL)
• IFN-λ (human IL28B): add directly to medium (100ng/mL)
• LPS: add directly to medium (1ng/mL-10µg/mL)
• CpG: add directly to medium (10µg/mL)
Silverstain of SDS-PAGE gels
• wash gel 2x 5min H2O
• fix gel 2x 15 min in 30% ethanol 10% acetic acid
• wash gel 2x 5 min 10% ethanol
• wash gel 2x 5 min H2O
• incubate 1 min with Sensitizer solution (0.1mL/50mL H2O)
• wash 2x 1 min H2O
• stain 30 min with Stain Working Solution (1mL Enhancer + 50 mL Stain)
• wash 2x 20 sec H2O
• develop until bands appear
• stop reaction with 5% acetic acid for 10 min
• put gel onto Whatman or onto Saran foil, can be dried with vacuum drier
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PAS staining of SDS-PAGE gels
• fix gel with 40% ethanol 10% acetic acid 0.5-1h
• incubate in 1% periodic acid 7% acetic acid for 30 min
• incubate in 7% acetic acid for 30 min
• apply Schiff's reagent for 30 min
• wash with water 30 min
Also unsuccessful staining of mucins attempted according to “Staining of Glycoproteins/Proteoglycals 
in SDS-Gels” (paragraph 3.2), Moller and Poulsen, Protein Protocols Handbook, 2nd edition
RNA isolation with Trizol (colonies from agar)
• pass gel pieces with 1 mL Trizol through needle until homogenous
• add 200 µL chloroform, shake 15 sec and incubate 5 min RT
• centrifuge 15 min 12 000 rpm 4 degC
• take out water (upper) phase and mix it with 500 µL of isopropanol
• incubate 10 min RT
• centrifuge 10 min 12 000 rpm 4 degC
• remove s/n, put 1 mL 75% ethanol
• centrifuge 5 min 7 500 rpm 4 degC
• remove ethanol by pipette and air-dry pellet (do not dry too much)
• resuspend pellet in 200 µL water (DEPC, o not use DEPC water if RNA to be used for 
microarray), incubate 10 min at 55 degC 300 rpm
• add 20 µL 3M sodium acetate (pH 5.2) and 500 µL 96% ethanol
• precipitate o/n at 20 degC
• centrifuge 30 min full speed 4 degC
• remove s/n, wash pellet with 1mL 75% ethanol
• centrifuge 10 min full speed 4 degC
• rmeove ethanol, air-dry pellet
• resuspend in 30 µL H2O (DEPC) 10 min 55 degC 300 rpm
• store at -80 degC
• chloroform: mix 49+1 with isoamyl alcohol, add 2 mL autoclaved H2O, shake, resolve phases, 
remove H2O, repeat 3x, leave some H2O over chloroform, store in dark
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